Oppenheimer more confident Perspective’s VMT update will build on prior results

Oppenheimer reiterated an Outperform rating and $14 price target on Perspective Therapeutics (CATX) after the firm hosted the company’s leadership team for an investor dinner last week. The firm said it came away with increased confidence that the VMT-alpha-NET update at ESMO on October 20 will build on prior results presented this summer at ASCO, while cautioning on setting a bar for response rates given the uncertainty on the length of follow-up for these patients. The 6mCi dose seeks to improve efficacy while preserving the safety margin or VMT-alpha-NET, and management seems confident in 5mCi as a potential go-forward dose in a registrational trial, the analyst tells investors in a research note.